Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Atara Biotherapeutics (ATRA) Return on Sales (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Return on Sales for 4 consecutive years, with 1.25% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Sales fell 70.0% year-over-year to 1.25%, compared with a TTM value of 0.72% through Sep 2025, up 203.0%, and an annual FY2024 reading of 0.0%, up 3221.0% over the prior year.
  • Return on Sales was 1.25% for Q3 2025 at Atara Biotherapeutics, down from 0.14% in the prior quarter.
  • Across five years, Return on Sales topped out at 2.42% in Q4 2022 and bottomed at 89.67% in Q2 2023.
  • Average Return on Sales over 4 years is 16.34%, with a median of 0.91% recorded in 2024.
  • The sharpest move saw Return on Sales crashed -1482bps in 2023, then soared 8900bps in 2024.
  • Year by year, Return on Sales stood at 2.42% in 2022, then plummeted by -612bps to 12.4% in 2023, then surged by 118bps to 2.22% in 2024, then tumbled by -156bps to 1.25% in 2025.
  • Business Quant data shows Return on Sales for ATRA at 1.25% in Q3 2025, 0.14% in Q2 2025, and 0.39% in Q1 2025.